0001415889-24-008760.txt : 20240320 0001415889-24-008760.hdr.sgml : 20240320 20240320170011 ACCESSION NUMBER: 0001415889-24-008760 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240318 FILED AS OF DATE: 20240320 DATE AS OF CHANGE: 20240320 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stewart Jeffrey Ryan CENTRAL INDEX KEY: 0001761675 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 24768448 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 4 1 form4-03202024_050301.xml X0508 4 2024-03-18 0001551152 AbbVie Inc. ABBV 0001761675 Stewart Jeffrey Ryan 1 N. WAUKEGAN ROAD NORTH CHICAGO IL 60064 false true false false EVP, CHIEF COMMERCIAL OFFICER 0 Common Stock, $0.01 par value 2024-03-18 4 M 0 26110 61.36 A 119890 D Common Stock, $0.01 par value 2024-03-18 4 S 0 26110 178.85 D 93780 D Common Stock, $0.01 par value 2024-03-18 4 S 0 5099 179.03 D 88681 D Common Stock, $0.01 par value 2024-03-18 4 S 0 27740 178.69 D 60941 D Common Stock, $0.01 par value 1338 I By spouse in trust Option (Right to Buy) 61.36 2024-03-18 4 M 0 26110 61.36 D 2018-02-16 2027-02-15 Common Stock 26110 0 D The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.85 to $178.95, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.00 to $179.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.60 to $178.87, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reporting person disclaims beneficial ownership of all securities held by his spouse. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. T.O. Odutayo, attorney-in-fact for Jeffrey R. Stewart 2024-03-20